The Efficacy And Safety Of Sorafenib In Patients Of The Hepatocellular Carcinoma Recurrence After Liver Transplantation

Obiective:The aim of my study was to assess the efficacy and safety of sorafen ib in patients with recurrent hepatocellullar carcinoma following liver transplantion.Methods:This topic used retrospective analysis. Collected the patients who we-re diagnosised as primary hepatocellular carcinoma by pathological examination after receiving liver transplantation in institute from January 2009 to december 2015.All p-atients were diagnosised as hepatocellu-lar carcinoma recurrencing by imaging studies and serum AFP examination. All pati-ents underwent local therapy.The patients were divided into the treatment group and the control group depending on whether the use of sorafenib targeted therapy. Analys-is the differences between the two groups on OS and PFS. Explore sorafenib for hepatocellular carcinoma recurrence and metastasis after liver transplantation patient s-afety.Results:1.The treatment group and the control group 1 year,2 years,3 year overall survi val rates were 64.2% vs 26.7%,35.7% vs20.0%,7.1% vs6.7%. The mOS of the treatm ent group and the control group were 14.5 months and nine months. There was statis tically significant difference between the mOS of the treatment group and the control group (P=0.037). There was statistically significant difference between the treatmen t group and the control group in survival prognosis (P=0.030) by using multivariate Cox regression analysis.2. The treatment group and the control group 3 month,6 months,12 months for the disease-free survival rates were 100% vs73.3%,42.9% vs40.0%,7.1% vs6.7%. Th e mPFS of the treatd ment group and thd control group was 11 months and 4 months. There was no statistically significant difference between the mPFS of the treatment group and the control group (P=0.066). The immunosuppression, topical treatment, t umor recurrence number of lesions, rejection, or not use sorafenib were not statisticall y significant difference between the treatment group and the control group in progressi on-free survivalsurvival prognosis (P>0.05) by using multivariate Cox regression anal ysis.3. The treatment group appeared bone marrow suppression, hand-foot syndrome, skin rashes and itching, mainly concentrated in 0-2 grade.One case of treatment group appeared the syndroms of III degree of bone marrow suppression, three degree of ha nd-foot syndrom, and three degree of gastrointestinal symptoms that can not been toler ated.The syndroms disppeard after withdrawal. One patient appeared lower gastrointestin al bleeding adverse events was forced to terminate take medicine. One occurred serve r ejection after withdrawal one month because of tumor progression.It can not be exclud ed that sorafenib increases the risk of rejection.Conclusion:1.The survival time recurrence after liver transplantation in patients receiving topic al treatment combined sorafenib targeted therapy were longer than alone topical treat ment group, not the PFS.2.Patients with liver cancer recurrence and metastasis after liver transplantation gi ven sorafenib targeted therapy has better security, basically to sorafenib toxicity well t olerated.